LENOVO
19.1.2023 15:57:42 CET | Business Wire | Press release
Today, Lenovo (HKSE: 992) (ADR: LNVGY) announced its goal to reach net-zero greenhouse gas (GHG) emissions by 2050, validated and approved by the Science Based Targets initiative (SBTi), a partnership between the UN Global Compact, CDP and World Wide Fund for Nature – making it the first PC and smartphone maker and one of only 139 companies in the world with a net-zero target validated by SBTi.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230119005499/en/
By working with SBTi and aligning to their Net-Zero Standard (the world’s first), Lenovo is taking a scientific, collaborative and accountable approach to reducing emissions.
“As a global technology leader, Lenovo has been committed to reducing its emissions for more than a decade,” said Lenovo Chairman Yuanqing Yang. “In the fight against climate change, we believe collaboration and accountability are the two critical elements needed for collective success. We remain dedicated to following climate science, standardizing our measurements, and seeking ongoing validation for our targets and progress.”
Aligning goals to the SBTi helps hold companies accountable for their emissions reduction. Without aligning to SBTi, it is difficult to validate or know when a net-zero target is reached. This is because:
- Standardization: SBTi is the first body to standardize what net-zero means as it relates to the effort to limit global warming to 1.5 degrees Celsius.
- Adaptation: SBTi’s standard is dynamic and responsive to companies’ collective effort and the changing temperature of the planet.
- Accountability: While 2050 seems far away for many, many leaders making commitments today may not be in their positions in 27 years. Aligning goals to reduce climate change to an external body provides accountability and continuity.
“Climate science tells us that we need rapid and deep emissions cuts if we are to achieve global net-zero and prevent the most damaging effects of climate change,” said Luiz Amaral, Chief Executive Officer of the Science Based Targets initiative. “Lenovo’s net-zero targets match the urgency of the climate crisis and set a clear example that their peers must follow.”
Lenovo’s long-term 2050 goals coincide with its near-term, SBTi-validated 2030 emissions reduction goals, all of which are outlined below:
Overall Net-Zero Target
Lenovo commits to reach net-zero GHG emissions across the value chain by FY2049/2050.
Near-Term Targets
Lenovo commits to reduce absolute scope 1 and scope 2 GHG emissions 50% by FY2029/2030 from a FY2018/2019 base year. Lenovo also commits to reduce scope 3 GHG emissions from use of sold products 35% on average for comparable products within the same timeframe. Lenovo commits to reduce scope 3 GHG emissions from purchased goods and services 66.5% per million US$ gross profit within the same timeframe. Lenovo further commits to reduce scope 3 GHG emissions from upstream transportation and distribution 25% per tonne-km of transported product by within the same timeframe.
Long-Term Targets
Lenovo commits to reduce absolute scope 1, 2, and 3 GHG emissions by 90% by FY2049/50 from a FY2018/19 base year.
Lenovo is an early adopter of the science-based emissions reduction approach, after receiving approval for near-term 2030 emissions reduction goals in 2020 and helping to road test the first of its kind Net-Zero Standard.
“Success in achieving net-zero depends on a transparent, science-based and collaborative framework that will keep organizations accountable for the long run. SBTi has created that framework and will empower companies to expedite emissions reduction,” commented Carolina Milanesi, Founder of The Heart of Tech, an ESG-focused consultancy.
Primary strategies for reducing Lenovo’s emissions include reducing the environmental impact of its products, harnessing innovation to increase sustainability in its manufacturing, and decreasing emissions across its operations and value chain. These strategies have been outlined in the company’s Journey to Net-Zero video series, which demonstrates how Lenovo’s experts are changing business processes to meet net-zero targets.
Lenovo’s emissions measurements will contribute to a wider body of collaborative data to understand and limit climate change, in accordance with the Paris Agreement’s goal to limit warming to no more than 1.5 degrees Celsius above pre-industrial levels. More than 4,000 companies around the world are in the process of aligning their emissions reduction goals to SBTi’s science-based methodology and validation processes.
In addition to its work to reduce emissions, Lenovo has been recognized in Gartner’s Top 25 Global Supply Chain, Fortune’s World’s Most Admired Companies, and as a leader in Climate Change and Water Security by CDP. Read more about Lenovo’s efforts to create a smarter, more sustainable future for all in the company’s FY 2021-22 ESG Report.
For more information visit Lenovo StoryHub.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$70 billion revenue global technology powerhouse, ranked #171 in the Fortune Global 500, employing 82,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver smarter technology for all, Lenovo has built on its success as the world’s largest PC company by further expanding into key growth areas including server, storage, mobile, solutions and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com,and read about the latest news via our StoryHub.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005499/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release
Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
